<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17425" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Amantadine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chang</surname>
            <given-names>Carol</given-names>
          </name>
          <aff>Rush University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ramphul</surname>
            <given-names>Kamleshun</given-names>
          </name>
          <aff>Shanghai Jiao Tong University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Carol Chang declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kamleshun Ramphul declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>24</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17425.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Amantadine is an antiviral agent with mild antiparkinsonian activity. Amantadine was used in the early 2000s for Influenza A treatment. However, high levels of resistance have emerged recently, initially from Asia and now in North America. As of 2011, the CDC does not recommend treatment or prophylaxis of influenza A due to the high levels of resistance. Amantadine is now used mostly for Parkinson disease. This activity outlines the indications, contraindications, activity, adverse drug reactions, warning, precautions, toxicity, and limitations of amantadine in the clinical setting as relates to the essential points necessary for members of an interprofessional team managing the care of patients with Parkinson disease.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the proper indications for amantadine therapy.</p></list-item><list-item><p>Describe the mechanism of action of amantadine.</p></list-item><list-item><p>Review the potential adverse effects of amantadine.</p></list-item><list-item><p>Outline the importance of collaboration and coordination among the interprofessional team and how it can enhance patient care when dosing amantadine to improve patient outcomes for Parkinson patients.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17425&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17425">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17425.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Amantadine is an antiviral agent with mild antiparkinsonian activity. Amantadine was used in the early 2000s for Influenza A treatment.&#x000a0;A 2006 meta-analysis showed that the drug decreased influenza symptoms by one day and decreased the severity of fever and other symptoms. However, high resistance levels have emerged recently, initially from Asia and now in North America.&#x000a0;As of 2011, the CDC does not recommend treatment or prophylaxis of influenza A due to the high resistance levels.<xref ref-type="bibr" rid="article-17425.r1">[1]</xref>&#x000a0;</p>
        <p>Amantadine is now used mostly for Parkinson disease. Clinical trials have shown that amantadine decreases bradykinesia, rigidity, and tremor symptoms. There is a combined synergistic effect with added levodopa, which is converted to dopamine by striatal enzymes in the CNS. There can be a transient benefit to the drug, so short-term therapy for patients with the mild disease is best.<xref ref-type="bibr" rid="article-17425.r2">[2]</xref><xref ref-type="bibr" rid="article-17425.r3">[3]</xref></p>
        <p>Besides the two FDA-approved usages of amantadine, a few other diseases can benefit from amantadine. Clinical trials have conflicting results for the reduction of chorea in Huntington disease. The 2012 American Academy of Neurology guidelines suggests amantadine is likely effective in decreasing chorea, although the degree of&#x000a0;effect is unknown.<xref ref-type="bibr" rid="article-17425.r4">[4]</xref>&#x000a0;Amantadine is a first-line agent for fatigue in multiple sclerosis. Amantadine may be useful in restless leg syndrome. However, data is limited to a small clinical trial. Amantadine has also been used in traumatic brain injuries. Initial studies had suggested that it may promote functional recovery. A clinical trial in 2012 concluded amantadine accelerated the pace of functional recovery in patients with severe traumatic brain injuries. However, there were no significant differences in overall improvement compared with the placebo group.</p>
        <p>
<bold>FDA-labeled Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Parkinson disease: Drug-induced extrapyramidal reactions</p>
          </list-item>
          <list-item>
            <p>Influenza A: Prophylaxis and treatment</p>
          </list-item>
        </list>
        <p>
<bold>Non-FDA Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Huntington disease: Chorea</p>
          </list-item>
          <list-item>
            <p>Multiple sclerosis: Fatigue</p>
          </list-item>
          <list-item>
            <p>Restless leg syndrome</p>
          </list-item>
          <list-item>
            <p>Traumatic brain injuries</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17425.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The mechanism of action&#x000a0;of amantadine is uncertain. Antiviral activity primarily interferes&#x000a0;with viral replication. Amantadine disrupts the transmembrane domain of the viral M2 protein, which prevents infectious viral nucleic acid entry into the host cell. It may also inhibit the assembly of influenza A virus isolates from each of the subtypes (H1N1, H2N2, and H3N2) during replication. Influenza B has a structurally different M2 protein, which makes amantadine ineffective.<xref ref-type="bibr" rid="article-17425.r5">[5]</xref></p>
        <p>In the treatment of Parkinson disease, studies have shown amantadine acts on dopamine neurons. Amantadine is a weak, non-competitive antagonist of the NMDA receptor, which increases dopamine release and prevents dopamine reuptake. Although amantadine does not have anticholinergic activity, there may be anticholinergic side effects such as dry mouth, urinary retention, and constipation clinically.<xref ref-type="bibr" rid="article-17425.r6">[6]</xref><xref ref-type="bibr" rid="article-17425.r7">[7]</xref></p>
      </sec>
      <sec id="article-17425.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Dosage Formulation</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Amantadine hydrochloride oral capsules and oral tablets: 100 mg</p>
          </list-item>
          <list-item>
            <p>Amantadine hydrochloride oral capsule ER 24 Hour: 68.5 mg, 137 mg</p>
          </list-item>
          <list-item>
            <p>Amantadine hydrochloride oral syrup: 50 mg / 5 mL</p>
          </list-item>
          <list-item>
            <p>Amantadine hydrochloride oral tablet ER 24 Hour: 129 gm, 193 mg, 258 gm</p>
          </list-item>
        </list>
        <p>
<bold>FDA Approved</bold>
</p>
        <p>Amantadine is typically administered orally once daily or in divided doses depending on the indication.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>For the treatment of influenza A, amantadine 200 mg daily or 100 mg twice daily should be administered within 24 to 48 hours after the onset of symptoms and should be continued for 24 to 48 hours after the symptoms have resolved. For prophylaxis, patients should continue treatment for the entirety of the influenza season.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For the treatment of Parkinson disease, amantadine is also given orally at 100 mg twice daily and increased to 200 mg twice daily as needed. Dosing should begin at 100 mg once daily for patients taking other parkinsonian drugs.</p>
          </list-item>
        </list>
        <p>
<bold>Non-FDA Approved</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Huntington chorea: 100 mg orally three to four times daily.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Multiple sclerosis-related fatigues: 100 mg orally twice daily, increasing to 200 mg twice daily as needed.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Restless leg syndrome: 100 mg orally daily, increasing to 300 mg per day as needed.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Traumatic brain injury: 100 mg orally twice daily, increasing to 200 mg twice daily as needed.</p>
          </list-item>
        </list>
        <p>
<bold>Discontinuation of Therapy</bold>
</p>
        <p>It is important not to discontinue amantadine abruptly as it can cause neuroleptic malignant syndrome-like symptoms, such as high fever, tachycardia, muscle rigidity, and altered mental status. Instead, reduce the dose by half for one week before discontinuing.</p>
        <p>
<bold>Patients with Renal Impairment</bold>
</p>
        <p>The clearance of amantadine greatly diminishes in elderly patients and patients with renal impairment. Therefore, dose modification merits consideration in such cases.<bold>&#x000a0;</bold>Depending upon Kidney function (creatinine clearance), the following dosage adjustments are recommended.</p>
        <p>Creatinine clearance (mL/min/1.73m): Dose for Amantadine hydrochloride IR capsules</p>
        <list list-type="bullet">
          <list-item>
            <p>If CrCL 30 to 50 mL/min: 200 mg on 1st day and followed by 100 mg each day after that.</p>
          </list-item>
          <list-item>
            <p>If CrCL 15 to 29mL/min: 200 mg 1st day and followed by 100 mg on alternate days.</p>
          </list-item>
          <list-item>
            <p>If CrCL 15 mL/min or lesser: 200 mg every seven days.</p>
          </list-item>
          <list-item>
            <p>If patients are on hemodialysis: 200 mg every seven days.</p>
          </list-item>
        </list>
        <p>
<bold>Patients with Hepatic Impairment</bold>
</p>
        <p>Exercise caution when amantadine is used in patients with liver diseases. There are rare reports on the reversible elevation of AST, ALT, and other liver enzymes in patients using amantadine. Although this relationship is not established, care needs to be taken when used in patients with pre-existing hepatic impairment.<xref ref-type="bibr" rid="article-17425.r8">[8]</xref></p>
        <p>
<bold>Pediatric Considerations</bold>
</p>
        <p>There is a lack of safety and efficacy data on amantadine in infants below the age of one year.</p>
        <p>
<bold>Geriatric Considerations</bold>
</p>
        <p>Amantadine is primarily excreted in the urine; it accumulates in the plasma and the body if renal function is declined.&#x000a0;Hence the dose of amantadine should be decreased in individuals 65 years of age or older patients or patients with renal impairment. The dose of amantadine may need a reduction in patients with peripheral edema, congestive heart failure, or orthostatic hypotension.</p>
      </sec>
      <sec id="article-17425.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The main advantage of amantadine is that it has a low side effect profile. The primary adverse effects of amantadine may include&#x000a0;orthostatic hypotension, syncope, peripheral edema, dizziness, delusions, hallucinations, falls, xerostomia, and constipation. Although&#x000a0;livedo reticularis is a less common side effect, amantadine is&#x000a0;one of the best-known drugs to cause it. This side effect is reversible with the withdrawal of medication. Serious adverse effects include neuroleptic malignant syndrome, psychosis, suicidal ideation, and CNS depression. Central nervous system (CNS) depression requires monitoring, especially in the elderly. Providers should caution patients against&#x000a0;activities that require physical and mental alertness, such as driving and avoid combination with other CNS depressing agents, such as alcohol. Caution with usage and dosage adjustments may be necessary for those with heart disease, seizure disorder, hepatic impairment, and renal impairment.<xref ref-type="bibr" rid="article-17425.r2">[2]</xref></p>
      </sec>
      <sec id="article-17425.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Amantadine is contraindicated in patients with hypersensitivity to the drug or components of the formulation. The drug undergoes renal excretion, so the extended-release dosage form is contraindicated in patients with end-stage renal disease. Due to the possible anticholinergic side effects, patients with glaucoma or prostate hypertrophy should use with caution.</p>
        <p>Amantadine is an FDA category C for pregnancy. Researchers have observed teratogenic events in multiple animal reproduction studies. Clinicians should select another antiparkinsonian agent for pregnant patients with Parkinson disease unless the benefits outweigh the risks. Amantadine is present in breast milk. It can influence the production and excretion of breast milk. Physicians should properly advise and weigh out the risk of infant exposure, the benefits of breastfeeding, and the benefits of the drug to the mother before starting the medication.<xref ref-type="bibr" rid="article-17425.r9">[9]</xref></p>
      </sec>
      <sec id="article-17425.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>When administering amantadine, monitor blood pressure, renal function, and mental statuses, such as depression/suicidality, and psychosis. Those with seizure disorders have to be monitored for seizure activity. Patients with heart failure require vigilance for increased water retention and lower leg edema. Clinicians also need to watch liver enzymes in patients with liver disease as an irreversible elevation in transaminases has been reported.<xref ref-type="bibr" rid="article-17425.r10">[10]</xref><xref ref-type="bibr" rid="article-17425.r11">[11]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Renal function: Elevation in Creatinine and BUN, reduction in GFR</p>
          </list-item>
          <list-item>
            <p>Mental status: Hallucinations, delusions, depression, suicidality</p>
          </list-item>
          <list-item>
            <p>Blood pressure: Orthostatic hypotension</p>
          </list-item>
          <list-item>
            <p>LFT: Increase in AST and ALT</p>
          </list-item>
        </list>
        <p>There is an association between Parkinson disease and the incidence of melanoma. Patients should be closely monitored and have periodic skin examinations.</p>
      </sec>
      <sec id="article-17425.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There currently&#x000a0;is no minimum toxicity dose listed. The limitation for increased doses beyond 400 mg per day is due to CNS effects. It is essential to know the patient's history of mental illness and seizures before proceeding with therapy. Toxicity may manifest as acute psychosis, cardiovascular toxicity, coma, and/or death. Although there is no antidote for amantadine, side effects resolve with discontinuation of usage. Some&#x000a0;preparations of the drug&#x000a0;may contain propylene glycol. Large amounts of propylene glycol can potentially be toxic and cause hyperosmolality, lactic acidosis, respiratory depression, and seizures.&#x000a0;In addition, Amantadine toxicity is a concern in patients with severe renal impairment, as 90% of the dose administered orally is excreted unchanged in the urine.<xref ref-type="bibr" rid="article-17425.r12">[12]</xref></p>
      </sec>
      <sec id="article-17425.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Amantadine was once widely prescribed for Parkinson disease and even influenza. However, there are many more&#x000a0;effective drugs on the market, and the use of amantadine has declined. Nevertheless, nurse practitioners, physician assistants, or primary care providers who prescribe this agent should closely monitor the patient for adverse effects. Also, the patient's renal function and mental status require monitoring. Amantadine can increase the risk of depression and lower the threshold for seizures, so nurses should explicitly query and search for this information on patient intake. Irreversible changes in the liver can occur, and hence liver enzymes require monitoring at the same time. Pharmacists should examine the patient's medical record, look for drug interactions, verify dosing, and express any concerns to the prescriber. With an interprofessional team approach to healthcare, amantadine therapy can be most effective in those cases where it is still useful, and other agents can substitute for it with a collaborative assessment of the patient's needs and regimen. [Level V]</p>
      </sec>
      <sec id="article-17425.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17425&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17425">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17425/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17425">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17425.s11">
        <title>References</title>
        <ref id="article-17425.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naderi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Faghih</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Aqamolaei</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mortazavi</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Mortezaei</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sahebolzamani</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rezaei</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Akhondzadeh</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive-compulsive disorder: A double-blind randomized trial with placebo control.</article-title>
            <source>Psychiatry Clin Neurosci</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>73</volume>
            <issue>4</issue>
            <fpage>169</fpage>
            <page-range>169-174</page-range>
            <pub-id pub-id-type="pmid">30488617</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17425.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Draga&#x00161;evi&#x00107;-Mi&#x00161;kovi&#x00107;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Petrovi&#x00107;</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Stankovi&#x00107;</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kosti&#x00107;</surname>
                <given-names>VS</given-names>
              </name>
            </person-group>
            <article-title>Chemical management of levodopa-induced dyskinesia in Parkinson's disease patients.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>219</fpage>
            <page-range>219-230</page-range>
            <pub-id pub-id-type="pmid">30411647</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17425.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Machado-Alba</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Calvo-Torres</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Gaviria-Mendoza</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Castrill&#x000f3;n-Spitia</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Prescribing patterns of antiparkinson drugs in a group of Colombian patients, 2015.</article-title>
            <source>Biomedica</source>
            <year>2018</year>
            <month>Sep</month>
            <day>01</day>
            <volume>38</volume>
            <issue>3</issue>
            <fpage>417</fpage>
            <page-range>417-426</page-range>
            <pub-id pub-id-type="pmid">30335247</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17425.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scotti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Spinnler</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Amantadine and Huntington's chorea.</article-title>
            <source>N Engl J Med</source>
            <year>1971</year>
            <month>Dec</month>
            <day>02</day>
            <volume>285</volume>
            <issue>23</issue>
            <fpage>1325</fpage>
            <page-range>1325-6</page-range>
            <pub-id pub-id-type="pmid">4255886</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17425.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Okigbo</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Helkowski</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Royes</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Bleimeister</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Bao</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Bondi</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Kline</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Dose-dependent neurorestorative effects of amantadine after cortical impact injury.</article-title>
            <source>Neurosci Lett</source>
            <year>2019</year>
            <month>Feb</month>
            <day>16</day>
            <volume>694</volume>
            <fpage>69</fpage>
            <page-range>69-73</page-range>
            <pub-id pub-id-type="pmid">30472358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17425.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nikolaus</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wittsack</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Beu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Antke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hautzel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wickrath</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller-Lutz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Souza Silva</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Huston</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Antoch</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>HW</given-names>
              </name>
            </person-group>
            <article-title>Amantadine enhances nigrostriatal and mesolimbic dopamine function in the rat brain in relation to motor and exploratory activity.</article-title>
            <source>Pharmacol Biochem Behav</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>179</volume>
            <fpage>156</fpage>
            <page-range>156-170</page-range>
            <pub-id pub-id-type="pmid">30639878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17425.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bailey</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>TW</given-names>
              </name>
            </person-group>
            <article-title>The mechanism of action of amantadine in Parkinsonism: a review.</article-title>
            <source>Arch Int Pharmacodyn Ther</source>
            <year>1975</year>
            <month>Aug</month>
            <volume>216</volume>
            <issue>2</issue>
            <fpage>246</fpage>
            <page-range>246-62</page-range>
            <pub-id pub-id-type="pmid">1180616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17425.r8">
          <label>8</label>
          <element-citation publication-type="book">
            <chapter-title>Amantadine</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>6</month>
            <day>22</day>
            <pub-id pub-id-type="pmid">31643287</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17425.r9">
          <label>9</label>
          <element-citation publication-type="book">
            <chapter-title>Amantadine</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>10</month>
            <day>31</day>
            <pub-id pub-id-type="pmid">30000367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17425.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sreedharan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Devadathan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pathan</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Chalipat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mohammed</surname>
                <given-names>KPA</given-names>
              </name>
            </person-group>
            <article-title>Amantadine for the Treatment of Refractory Absence Seizures in Children.</article-title>
            <source>J Pediatr Neurosci</source>
            <year>2018</year>
            <season>Apr-Jun</season>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>131</fpage>
            <page-range>131-136</page-range>
            <pub-id pub-id-type="pmid">30090124</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17425.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Isaacson</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Fahn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pahwa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tanner</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Espay</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Trenkwalder</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Adler</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Patni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102.</article-title>
            <source>Mov Disord Clin Pract</source>
            <year>2018</year>
            <season>Mar-Apr</season>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>183</fpage>
            <page-range>183-190</page-range>
            <pub-id pub-id-type="pmid">29780852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17425.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Macchio</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sahgal</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Amantadine-induced coma.</article-title>
            <source>Arch Phys Med Rehabil</source>
            <year>1993</year>
            <month>Oct</month>
            <volume>74</volume>
            <issue>10</issue>
            <fpage>1119</fpage>
            <page-range>1119-20</page-range>
            <pub-id pub-id-type="pmid">8215867</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
